CD38 Monoclonal Antibody (HB7), PE, eBioscience™, Invitrogen™

Description

Description: The HB7 monoclonal antibody reacts with the human CD38 molecule, an approximately 45 kDa type II transmembrane protein. CD38 is an ectoenzyme which catalyses NAD into nicotinic acid adenine dinucleotide phosphate (NAADP) and cyclic ADP-ribose (cADPR), both of which are secondary messengers. Expression of CD38 is bimodal during B cell development, modulating from high in immature cells to low in intermediate ones and back to high on mature B cells. Additionally CD38 is found in a variety of tissues and other hematopoietic cells (e.g. T cells, NK cells and monocytes) and can be used to phenotype leukemias and monitor HIV-1 progression. The CD34+CD38- population of hematopoietic stems cells is thought to define the most pluripotent cells (e.g. blast colony forming cells). In addition to surface expression, CD38 has recently been found in the nucleus where it may play a role in monitoring calcium levels. Applications Reported: This HB7 antibody has been reported for use in flow cytometric analysis. Applications Tested: This HB7 antibody has been pre-titrated and tested by flow cytometric analysis of normal human peripheral blood cells. This can be used at 5 µL (0.06 µg) per test. A test is defined as the amount (µg) of antibody that will stain a cell sample in a final volume of 100 µL. Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test.

Excitation: 488-561 nm; Emission: 578 nm; Laser: Blue Laser, Green Laser, Yellow-Green Laser. Filtration: 0.2 μm post-manufacturing filtered. CD38 (NAD+ glycohydrolase) is a type II transmembrane glycoprotein able to induce activation, proliferation and differentiation of mature lymphocytes and mediate apoptosis of myeloid and lymphoid progenitor cells. CD38 functions as a multi-catalytic ectoenzyme serving as ADP-ribosyl cyclase, cyclic ADP-ribose hydrolase and possibly NAD+ glycohydrolase or as a cell surface receptor. Antibodies to CD38 are useful in subtyping of lymphomas and leukemias, detection of plasma cells (i.e. identification of myelomas), and as a marker for activated B and T cells. CD38 participates in cell adhesion, signal transduction and calcium signaling. Further, CD38 is expressed at high levels in the pancreas, liver, kidney, maligt lymphoma and neuroblastoma. Diseases associated with CD38 dysfunction include chronic lymphocytic leukemia and Richter’s Syndrome.